Latest On-Demand Webinars

The popularity of mRNA-based therapeutics continues to grow as their ability to express the target of interest continues to improve. The challenge that scientists now face is how to scale up production to make these novel therapeutics available for use.

Accelerating the development of mRNA vaccines and therapeutics requires the selection and use of raw materials designed to meet critical process, scale, quality and regulatory needs. Choosing appropriate materials saves scientists both time and money.

This webinar discusses an analytical approach for N-linked glycan analysis using the SLIM-based high-resolution ion mobility platform MOBIE. Results will be shown for each aspect of the overall strategy and how this platform can be an integral part for the characterization of protein therapeutics.

Attend this webinar to:
- Overcome key challenges when working with rare antigen-specific T cells
- Learn the key considerations when preparing samples for single-cell sequencing
- Gain insights into tumor single-cell sequencing results

Improvements in cytometer technology as well as the increased access to suitable dyes with desirable characteristics have been critical factors in improving the utility of flow cytometry as a drug discovery platform.

A major concern for those intending to bring cell and gene therapy products to market is the manufacturing needs as the product moves from small- to large-scale.

The momentous success of mRNA vaccines has prompted the exploration of new analytical approaches for supporting the development, production and deployment of new nucleic acid therapeutics.

The number of viral vector-based gene therapies in clinical trials has recently grown into the thousands due to the tremendous genetic disease-curing potential they harbor. Yet the comprehensive characterization of critical quality attributes for the safety and efficacy of the material produced for these trials remains a challenge for both manufacturers and regulatory bodies alike.

Biotherapeutics such as monoclonal antibodies and other proteins are routinely analyzed by size exclusion chromatography (SEC) to detect high and low molecular weight impurities (aggregates or fragments). Predominantly, UV absorbance is used for detection. However, advanced detection technologies namely multiangle light scattering (MALS) and mass spectrometry (MS) better characterize proteins and reveal species hidden in UV chromatograms.

This webinar will explain the different detection methods and their results. Special emphasis will be placed on the higher requirements for size exclusion columns preceding advanced detection methods.

In this webinar, we will explore how retinal organoids are used as a platform to assess the safety and efficacy of retinal gene therapy treatments.